Updates

Ref: BCIL/SE/2026/66 November 04, 2026 To, To, The Secretary, The Manager, BSE Limited, Listing Department, Phiroze Jeejeebhoy Towers, National Stock Exchange of India Limited, Dalal Street, Exchange Plaza, C-1, G Block, Bandra-Kurla, Mumbai - 400 001 Complex, Bandra (East), Mumbai – 400 051 Scrip Code: 531719 Symbol: BHAGCHEM Sub: Investor Presentation Dear Sir/Madam, Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015, we enclose herewith Investors Presentation on the Financial Highlights for the quarter ended September 30, 2026. The copy of the same is also available on the website of the Company i.e. https://www.bhagirad.com/ Kindly take the same on record and display on the website of your exchange. Thanks & Regards, For Bhagiradha Chemicals and Industries Limited, Sharanya. M Company Secretary & Compliance Officer M. No: F13842 Bhagiradha Chemicals & Industries Limited Q2 & H1 FY27 InvestorPresentation Safe Harbor This presentation and the accompanying slides (the “Presentation”), which have been prepared by Bhagiradha Chemicals and Industries Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offeringdocument containing detailed informationabout the Company. This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of,or any omissionfrom,this Presentation is expressly excluded. Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company’s ability to successfully implement its strategy, the Company’s future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows,the Company’s market preferences and its exposure to market risks, as well as other risks. The Company’s actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third party statements and projections Q2 & H1 FY27 Results Highlights H1FY27 Consolidated Financial Highlights Revenue From Operations EBITDA PAT Volumes: Rs. In Crores • Volumes improved supported by new molecule introductions and the ramp-up of Bheema Fine Chemicals, +38% +121% +98% despite softer demand conditions during Q2. 364.9 53.2 18.7 Price Realizations: 263.9 • Average realisations was better compared to the 24.0 corresponding period last year. Revenue: • Revenue growth was driven by higher volumes, with H1FY26 H1FY27 H1FY26 H1FY27 H1FY26 H1FY27 major contributions from higher-margin products. Gross Margins: Gross Margin (%) EBITDA Margin (%) PAT Margin (%) • Gross margins improved, supported by a higher contribution from better-margin products. 39.8% 14.6% 5.1% EBITDA: 34.2% • EBITDA growth was driven by healthy volumes and 3.6% 9.1% improved operating efficiencies. PAT: • PAT nearly doubled, reflecting stronger operating performance, despite higher depreciation and finance costs associated with the ramp-up of Bheema Fine H1FY26 H1FY27 H1FY26 H1FY27 H1FY26 H1FY27 Chemicals plant. Q2FY27 Consolidated Financial Highlights Revenue From Operations EBITDA PAT Rs. In Crores Volumes & Price Realizations: +21.3% +50.9% • Volumes improved YoY, supported by new product 195.0 launches, while realisations remained broadly stable. 169.9 30.5 -1.8% 140.1 22.7 13.3 Revenue: 15.1 • Revenue growth was primarily driven by higher volumes, 5.5 5.4 with major contributions from higher-margin products. Gross Margins: Q2FY26 Q1FY27 Q2FY27 Q2FY26 Q1FY27 Q2FY27 Q2FY26 Q1FY27 Q2FY27 • Gross margins expanded YoY, supported by a favourable product mix and process improvements. Gross Margin (%) EBITDA Margin (%) PAT Margin (%) EBITDA: • EBITDA improved YoY, supported by higher capacity utilisation, a richer product mix and increased 41.1% contribution from higher-margin products. 38.6% 34.8% 15.7% PAT: 13.4% 6.8% 10.7% • PAT remained broadly flat YoY, as profitability faced some 3.9% pressure from higher depreciation and finance costs 3.2% associated with investments in the Bheema Fine Chemicals plant. Q2FY26 Q1FY27 Q2FY27 Q2FY26 Q1FY27 Q2FY27 Q2FY26 Q1FY27 Q2FY27 Consolidated Profit & Loss Statement Particulars (Rs. In Cr.) Q2FY27 Q2FY26 YoY Q1FY27 QoQ H1FY27 H1FY26 YoY FY26 Revenue From Operations 169.9 140.1 21% 195.0 -13% 364.9 263.9 38% 535.9 Cost of Raw Materials Consumed 100.1 91.4 119.8 219.9 173.6 335.2 Gross Profit 69.8 48.7 43% 75.2 -7% 145.1 90.3 61% 200.8 Gross Profit Margin (%) 41.1% 34.8% 38.6% 39.8% 34.2% 37.5% Employee Benefit Expenses 15.2 11.6 14.7 29.9 23.0 49.5 Other Expenses 31.9 22.1 30.0 61.9 43.3 94.2 EBITDA 22.7 15.1 51% 30.5 -26% 53.2 24.0 121% 57.1 EBITDA Margin (%) 13.4% 10.7% 15.7% 14.6% 9.1% 10.7% Depreciation & Amortization 9.0 4.0 8.3 17.4 7.8 20.9 EBIT 13.7 11.1 23% 22.2 -38% 35.9 16.2 121% 36.2 Interest Expense 7.6 4.1 6.4 14.1 7.3 17.5 Other Income 0.5 0.5 1.8 2.3 1.1 2.4 Exceptional Gain/Loss 0.0 0.0 0.0 0.0 0.0 0.0 Profit Before Tax 6.6 7.5 17.5 24.1 10.0 21.1 Tax Expense 1.2 2.0 4.2 5.4 0.5 2.9 Profit After Tax 5.4 5.5 -2% 13.3 -59% 18.7 9.5 98% 18.2 Profit After Tax Margin (%) 3.2% 3.9% 6.8% 5.1% 3.6% 3.4% Consolidated Balance Sheet Assets (Rs. In Cr.) Sep-26 Mar-26 Equity & Liabilities (Rs. In Cr.) Sep-26 Mar-26 Non- Current Assets (A) 712.6 683.7 Equity (A) 715.3 698.3 Property, Plant & Equipment 605.4 573.9 Equity Share Capital 13.0 13.0 Capital Work in Progress 90.6 94.2 Other Equity 702.3 685.4 Right use of Assets 4.3 4.5 Non-Current Liabilities (B) 223.3 176.3 Intangible Assets 1.2 1.5 Financial Liabilities Intangible Assets under Development 1.4 1.4 (i) Borrowings 199.1 153.1 Financial Assets (ii) Other Financial Liabilities & Lease Liabilities 2.1 3.0 (i) Others Financial Assets 6.7 6.6 Provisions 1.3 0.8 Other Non-Current Assets 3.1 1.5 Current Assets (B) 623.1 436.5 Deferred Tax Liabilities (net) 20.7 19.4 Inventories 262.2 145.8 Current Liabilities (C) 397.1 245.5 Financial Assets Financial Liabilities (i) Trade Receivables 277.4 204.7 (i) Borrowings 168.7 77.9 (ii) Investments 0.0 (ii) Trade Payables 193.8 138.1 (iii) Cash & Cash Equivalent 2.2 15.7 (iv) Other Financial Liabilities & Lease Liabilities 29.7 25.7 (iv) Bank Balance other than Cash 3.6 3.2 Other Current Liabilities 1.2 0.9 (v) Others Financial Assets 0.5 0.7 Provisions 2.6 2.9 Current Tax Assets (net) 0.8 0.8 Current Tax Liabilities (net) 1.0 0.0 Other Current Assets 76.4 65.6 Tota [Showing first 8,000 characters — download PDF for full document]